Stratatech Corp., a privately-held regenerative medicine company, announced that it has genetically modified its StrataGraft® living human skin substitute to actively fight costly bacterial infections that routinely develop at the site of burns and other severe skin injuries, such as skin ulcers. Bacterial infection is a primary cause of skin graft rejection and can significantly increase the hospital costs of burn and other skin injury patients. Stratatech’s skin-substitute innovation, detailed in an article published online this morning by the journal Molecular Therapy, enables the immediate topical delivery of a potent anti-infective that actively inhibits bacterial growth and promotes regrowth of the patient’s own cells.

Stratatech’s genetically-engineered skin substitute was generated using a non-viral vector, or carrier. The company believes it is the first time a virus-free approach has been used to genetically modify a living, cell-based tissue substitute. The data published in Molecular Therapy demonstrate that the modified tissue contained 139-fold more anti-infective proteins called host defense peptides than unmodified tissue in vitro.

Get the Latest Natural Anti Wrinkle Creams that will support your skin natural ability to repair it self, by improving collagen, elastin and protecting your skin from environment toxins.

02 Stratatech Engineers Skin Substitute With Potent Anti Infective Function

  • Share/Bookmark

Tagged with:

Filed under: skin care news

Like this post? Subscribe to my RSS feed and get loads more!

Possibly related posts